Insider buying last 90 days
No open-market insider purchases were filed for ONC in the last 90 days.
From Form 4 filings, dated to when each was filed.
BeOne Medicines closed at $411.29 on 16 November 2026, -1.3% on the day. The price sits above both the 50-day ($370.24) and 200-day ($328.15) moving averages, inside a 52-week range of $253.95 to $424.73. The GekkoIndex reads 47.9, in the Neutral zone, up 8.5 points over five sessions. Gekko Fair Value is $407.51, so the price is 0.9% above it.
The next earnings report is due on 25 February 2027, 100 days away (before open). Over the last 8 reports the company beat the earnings estimate 6 times, with an average move of 4.6% across the report. Seasonally, the next 20 trading days from this point averaged -11.3% over the last 5 years, rising in 1 of them.
12 firms rate the stock: 12 buy, 0 hold and 0 sell, with a consensus target of $465.00. A typical daily move is about 3.3%, and a typical 20-day move about 9.8%. On the swing-trade checklist, 2 items read supportive and 1 reads as a headwind (seasonality).
A plain summary of the figures as of the Nov 16, 2026 close.
BeOne Medicines scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
Above 50 and 200-day
Close $411.29 is above the 50-day ($370.24) and 200-day ($328.15) averages, and the 50-day is above the 200-day.
See the chart47.9, Neutral
Reading 47.9 is in the Neutral zone.
See the GekkoIndex0.4% above
Price is within 5% of Gekko Fair Value (0.4% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 100 days
Next report Feb 25, 2027, 100 days away — outside a typical 20-trading-day hold.
See earnings−10.9% on average
From this point in the calendar, the next 20 trading days averaged −10.9% over 5 years, rising in 1 of them.
See seasonalityA description of current data, not a recommendation. How this page works
BeOne Medicines closed at $411.29 on Nov 16, 2026, +11.7% over the past year, inside a 52-week range of $253.95 to $424.73.
Use the left and right arrow keys to read daily values.
Put ONC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
BeOne Medicines focuses on finding and developing treatments for cancer patients, with reach into the United States, China, Europe and other regions. Its marketed products include BRUKINSA, a treatment for several blood cancers; TEVIMBRA, an immunotherapy used against various solid tumors and blood cancers; SYLVANT, for adults with multicentric castleman disease; BAITUOWEI, used in certain breast cancer cases; and PARTRUVIX, for various solid tumors.
Beyond these approved therapies, the company runs a broad pipeline of experimental compounds targeting different cancer pathways, alongside earlier-stage preclinical work. It has established agreements with other pharmaceutical companies, including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis, reflecting collaborative ties across its research and development efforts.
The company was founded in 2010 and is headquartered in Basel, Switzerland. It previously operated under the name BeiGene, Ltd. before adopting its current name in May 2025. Its shares trade under the ticker ONC.
BeOne Medicines’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 47.9, in the Neutral zone, up 8.5 points over five sessions.
Up 8.5 points over five sessions, from the Distribution zone.
Reading for Nov 16, 2026
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 43 | +2.4% | +10.4% |
| Accumulation | 173 | +1.8% | +8.3% |
| Neutral (current zone) | 346 | +0.7% | +1.2% |
| Distribution | 84 | −0.2% | +1.8% |
| Selling | 14 | −0.7% | −4.3% |
Average ONC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
BeOne Medicines trades 0.4% above Gekko Fair Value of $409.84, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what BeOne Medicines shares are worth, recalculated every trading day.
$409.84
Gekko Fair Value, Nov 17, 2026
0.4% above fair value · About fair value
At the end of Aug 2026 the price was 9.0% below the estimate.
No open-market insider purchases were filed for BeOne Medicines, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for ONC in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in ONC were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
BeOne Medicines reports on Feb 25, 2027, before the open (100 days away), and beat the EPS estimate in 6 of its last 8 reports.
Feb 25, 2027
Expected before the open, 100 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 5, 2026 | $4.59 est $2.39 | $1.89B est $1.76B | +7.7% |
| Aug 5, 2026 | $2.05 est $1.40 | $1.71B est $1.62B | +2.1% |
| May 6, 2026 | $1.96 est $0.81 | $1.51B est $1.48B | +6.6% |
| Feb 26, 2026 | $0.58 est $1.60 | $1.50B est $1.47B | −10.0% |
| Nov 6, 2025 | $1.09 est $0.72 | $1.41B est $1.45B | −0.4% |
| Aug 6, 2025 | $0.84 est $0.48 | $1.32B est $1.44B | −2.9% |
| May 7, 2025 | $1.22 est −$0.71 | $1.12B est $1.25B | −2.4% |
| Feb 27, 2025 | −$1.43 est −$1.01 | $1.13B est $1.04B | +4.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for BeOne Medicines is $469.23, +14.1% from the last close, from 12 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 12 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Morgan Stanley | $476 | +15.7% |
| Nov 6 | Barclays | $446 | +8.4% |
| Nov 6 | Citizens JMP | $463 | +12.6% |
| Nov 6 | Truist Financial | $448 | +8.9% |
| Nov 6 | Morgan Stanley | $465 | +13.1% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 17, BeOne Medicines averaged −10.9% across the last 5 years, rising in 1 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −6.7% | 1 of 5 |
| Next 10 trading days | −3.0% | 2 of 5 |
| Next 15 trading days | −6.7% | 1 of 5 |
| Next 20 trading days | −10.9% | 1 of 5 |
| Next 30 trading days | −8.1% | 1 of 5 |
For scale, ONC’s typical 20-trading-day move in either direction is about 9.8%.
BeOne Medicines’s market cap is $43.95B, with a P/E ratio of 52.7 and revenue of $6.61B over the last twelve months.
1 headline about BeOne Medicines from the past week, newest first, each linking to the publisher.
BeOne Medicines’s market cap is $43.95B at the Nov 16, 2026 close of $411.29, with 105.4M shares outstanding. The shares trade on a P/E ratio of 52.7.
The consensus analyst 12-month price target for BeOne Medicines is $469.23, +14.1% from the last close. Of the 12 firms that rated the stock in the last 90 days, 12 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate BeOne Medicines is about fair value: the Nov 16, 2026 close of $411.29 is 0.4% above Gekko Fair Value of $409.84. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
BeOne Medicines is expected to report on Feb 25, 2027, before the market opens (100 days away). Analysts expect earnings of $3.32 per share on revenue of $1.88B. BeOne Medicines beat the earnings estimate in 6 of its last 8 reports, moving 4.6% on average across the report.
BeOne Medicines’s 52-week high is $424.73 and its 52-week low is $253.95; it closed at $411.29 on Nov 16, 2026, +11.7% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,476 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.